Regeneron Plunges 10% After Legal Shield Cracks — Is the Multi-Billion-Dollar Cash Cow Cooked?

Regeneron Pharmaceuticals just watched its stock plunge by nearly 10% in a single, brutal trading session. The catalyst? A federal judge in West Virginia denied their request to block Amgen from launching a competing biosimilar to their blockbuster eye drug, Eylea.In this episode of Implied, we break down how the legal moat around Regeneron’s absolute cash cow—which generates $1.5 billion in U.S. sales alone—just cracked wide open to generic competition. But while Wall Street is panicking over the undefeated patent cliff, are they completely blinding themselves to the double-digit growth of their anti-inflammatory mega-blockbuster, Dupixent? Tune in to find out if this drop is a classic market overreaction or a warning that Regeneron’s next chapter is going to be a bumpy ride.